Anhui Fengyuan Pharmaceutical (000153.SZ) subsidiary's tirofiban hydrochloride API approved for marketing
Fengyuan Pharmaceutical (000153.SZ) announced that recently, its wholly-owned subsidiary Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd. received the "Chemical API Marketing Application Approval Notification" for tirofiban hydrochloride issued upon approval by the National Medical Products Administration.
Anhui Fengyuan Pharmaceutical (000153.SZ) announced that recently, its wholly-owned subsidiary Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd. received the "Chemical API Marketing Application Approval Notice" for tirofiban hydrochloride issued by the National Medical Products Administration.
Tirofiban hydrochloride is a reversible antagonist of fibrinogen binding to the platelet surface GPIIb/IIIa receptor. Intravenous administration can inhibit platelet aggregation and is used in adult patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) to reduce the risk of early ischemic events such as myocardial infarction; it can also be used in patients with ST-segment elevation acute myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) to reduce the occurrence of major cardiovascular events.
Related Articles
HANSOH PHARMA (03692): Injection of Reconnective Votutamab (HS-20093) for the treatment of osteosarcoma included in the priority review and approval process of the National Medical Products Administration
.png)
CIMC ENRIC (03899) repurchased 200,000 shares for HK$1.456 million on September 22.
FIH (02038) spent HKD 948,300 to repurchase 60,000 shares on September 22.
HANSOH PHARMA (03692): Injection of Reconnective Votutamab (HS-20093) for the treatment of osteosarcoma included in the priority review and approval process of the National Medical Products Administration
CIMC ENRIC (03899) repurchased 200,000 shares for HK$1.456 million on September 22.
FIH (02038) spent HKD 948,300 to repurchase 60,000 shares on September 22.
